Takeda receives FDA approval for NINLARO (ixazomib) capsules to treat patients with multiple myeloma

November 25, 2015

Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration has approved NINLARO (ixazomib) capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a once-weekly pill.

Previous Article
Vitamin D supplements have no effect on frequency and severity of colds in asthma patients
Vitamin D supplements have no effect on frequency and severity of colds in asthma patients

Vitamin D supplements do not reduce the number or severity of colds in asthma patients, according to a new ...

Next Article
Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis
Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

Novartis announced today that the European Commission has approved Cosentyx (secukinumab) for the treatment...